BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

ChemoCentryx, Inc. Presents Data on CCX168, an Orally Administered Small Molecule Inhibitor of C5aR, at the 49th European Renal Association - European Dialysis and Transplant Association Congress


5/28/2012 11:13:03 PM

MOUNTAIN VIEW, Calif., May 26, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI - News), today announced the presentation of results from the Company's development program for CCX168, an investigational orally administered inhibitor of the complement anaphylatoxin receptor known as C5aR. CCX168 is currently in a multinational, randomized, double-blind, placebo-controlled Phase II clinical trial for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated renal vasculitis, an inflammation of small blood vessels in the kidney. ANCA-associated renal vaculitis can lead to renal failure and a high mortality if untreated. As presented in two posters at the 49th European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) Congress in Paris, France, Phase I clinical trial results, supported by findings from preclinical in vivo studies, established the target dosing level for the Company's ongoing Phase II clinical trial.

Read at News Release

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->